MIB Agents Now Accepting Letters of Intent for Research Grants
Aiming to further research for pediatric osteosarcoma, MIB Agents awards grants annually.
Grant Program Overview
MIB Agents is excited to announce that it is opening its doors for letters of intent (LOI) for its annual OutSmarting Osteosarcoma research grant program, inviting researchers to submit their innovative projects aimed at improving the lives of those affected by osteosarcoma. Since its inception in 2017, the program has been dedicated to funding essential research that targets this aggressive bone cancer, impacting an estimated 1,000 individuals annually in the U.S., many of whom are young children and teenagers.
Funding and Support
Over the past years, MIB Agents has awarded a remarkable total of $2.5 million, supporting 32 researchers in their quest for advancements in osteosarcoma research. The organization provides a $100,000 Hero award, recognizing outstanding contributions in the field, and a $50,000 Young Investigator Research Hope award to nurture the next generation of researchers. These awards play a crucial role in encouraging new ideas and fostering talent within the field.
Community Involvement and Collaboration
The unique aspect of MIB Agents’ grant initiative is the strong involvement of the community. Patients, families, and fundraising efforts collectively contribute to the creation of MIB Agents Family Funds, commemorating loved ones battling this disease, or remembering those who have passed. This collaboration not only enriches the research endeavors but also provides a sense of hope and unity among those affected by osteosarcoma.
Partnerships with Foundations
Additionally, the OutSmarting Osteosarcoma grants may receive support through collaborations with other charitable foundations dedicated to pediatric cancer research. These partnerships seek to back studies that have undergone rigorous scientific peer review, ensuring that only the most promising proposals receive funding.
Patient Voices in Research
MIB Agents prides itself on bridging the gap between the scientific community and patient experiences. The grant review process is detailed and inclusive, as family representatives participate as Stakeholder Reviewers, lending valuable insights on the proposals. Their involvement guarantees that patients' needs and perspectives are fundamental to the research that is funded.
Applying for an LOI
Those interested in applying can find detailed eligibility requirements and guidelines on the MIB Agents website. LOIs must be submitted through the Proposal Central online platform by the deadline. Following the submission, a peer review process will assess all proposals, and the top applicants will be invited to submit a full application shortly thereafter. Award notifications are expected to be communicated in early spring of the following year.
About MIB Agents
Founded in 2012 and gaining official 501(c)(3) nonprofit status in 2016, MIB Agents is a cornerstone in the fight against pediatric osteosarcoma. The organization aims to enhance the lives of patients and their families by providing support through various programs, educational initiatives, and research endeavors. MIB Agents is committed to making cancer research more effective and meaningful for all.
Frequently Asked Questions
What is the OutSmarting Osteosarcoma grant program?
The program provides funding for research aimed at improving treatment and outcomes for osteosarcoma patients.
Who can apply for the grants?
Researchers focused on innovative projects related to osteosarcoma can apply through the letter of intent submission process.
How much funding is available through the grants?
MIB Agents awards up to $100,000 for Hero awards and $50,000 for Young Investigator awards.
What role do families play in the grant process?
Families can contribute through Family Funds, raising money and participating in the grant review process, ensuring their voices are heard.
When is the deadline for submitting a letter of intent?
The deadline for LOI submission is announced on the MIB Agents website, typically set for late October.
